Changzhou Boweidi Pharmaceutical Co., Ltd. was established in November 2011 and commenced operations in October 2012. It is a high-tech biopharmaceutical enterprise founded by national high-level talents. The company currently has assets of 37.5 million yuan, a building area of 2,000 m², and 1,300 m² of Class 100,000 cleanrooms and supporting facilities. It is equipped with comprehensive production and testing equipment and advanced production processes, and currently has more than 60 employees (including senior talents such as Ph.D. and master's degree holders). Since its establishment, the company has carried out research and development of colloidal gold, fluorescence immunoassay, chemiluminescence, and molecular diagnostic products, mainly focusing on the clinical diagnosis of common and frequently occurring diseases such as cardiovascular and cerebrovascular diseases, infectious diseases, and tumors.
The company's operations are led by a series of cardiac marker colloidal gold rapid quantitative automated detection technology products, with follow-up support from dozens of rapid detection products for infectious diseases and malignant tumors accumulated over years of entrepreneurship, gradually establishing the company's brand and reputation in clinical testing markets at home and abroad.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows